{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:39:20Z","timestamp":1790797160021,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["Specialiste Doctorant 40011958"],"award-info":[{"award-number":["Specialiste Doctorant 40011958"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11102-024-01445-5","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:57:28Z","timestamp":1724050648000},"page":"625-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-9455","authenticated-orcid":false,"given":"Stefan Matei","family":"Constantinescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsalia","family":"Alexopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"1","key":"1445_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","volume":"23","author":"H Duskin-Bitan","year":"2020","unstructured":"Duskin-Bitan H, Shimon I (2020) Prolactinomas in males: any differences? Pituitary 23(1):52\u201357","journal-title":"Pituitary"},{"issue":"7","key":"1445_CR2","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/andr.13428","volume":"11","author":"Y Rudman","year":"2023","unstructured":"Rudman Y, Duskin-Bitan H, Richter I, Tsvetov G, Masri-Iraqi H, Akirov A et al (2023) Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men. Andrology 11(7):1398\u20131407","journal-title":"Andrology"},{"issue":"2","key":"1445_CR3","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"1445_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19(12):722\u2013740","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1445_CR5","first-page":"3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053\u20133057","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1445_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/A:1025377816769","volume":"5","author":"L Sibal","year":"2002","unstructured":"Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH et al (2002) Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5(4):243\u2013246","journal-title":"Pituitary"},{"issue":"3","key":"1445_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A et al (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64(3):307\u2013313","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1445_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/cen.12124","volume":"79","author":"N Karavitaki","year":"2013","unstructured":"Karavitaki N, Dobrescu R, Byrne JV, Grossman AB, Wass JA (2013) Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxf) 79(2):217\u2013223","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1445_CR9","doi-asserted-by":"crossref","unstructured":"Sehemby M, Lila AR, Sarathi V, Shah R, Sankhe S, Jaiswal SK et al (2020) Predictors of chronic LH-Testosterone Axis suppression in male Macroprolactinomas with Normoprolactinemia on Cabergoline. J Clin Endocrinol Metab. ;105(12)","DOI":"10.1210\/clinem\/dgaa650"},{"issue":"6","key":"1445_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","volume":"25","author":"Y Rudman","year":"2022","unstructured":"Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I (2022) Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6):882\u2013890","journal-title":"Pituitary"},{"issue":"4","key":"1445_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11102-022-01242-y","volume":"25","author":"KM Al Dahmani","year":"2022","unstructured":"Al Dahmani KM, Almalki MH, Ekhzaimy A, Aziz F, Bashier A, Mahzari MM et al (2022) Proportion and predictors of Hypogonadism Recovery in men with Macroprolactinomas treated with dopamine agonists. Pituitary 25(4):658\u2013666","journal-title":"Pituitary"},{"issue":"3","key":"1445_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11102-013-0497-x","volume":"17","author":"I Shimon","year":"2014","unstructured":"Shimon I, Benbassat C (2014) Male prolactinomas presenting with normal testosterone levels. Pituitary 17(3):246\u2013250","journal-title":"Pituitary"},{"issue":"1","key":"1445_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","volume":"101","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C et al (2015) Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology 101(1):66\u201381","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1445_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3171\/2019.3.JNS19121","volume":"133","author":"WT Burke","year":"2019","unstructured":"Burke WT, Penn DL, Castlen JP, Donoho DA, Repetti CS, Iuliano S et al (2019) Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J Neurosurg 133(2):321\u2013328","journal-title":"J Neurosurg"},{"issue":"1","key":"1445_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G et al (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53(1):53\u201360","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"14","key":"1445_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904\u2013909","journal-title":"N Engl J Med"},{"issue":"11","key":"1445_CR17","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1210\/jc.2008-0710","volume":"93","author":"R Kazlauskaite","year":"2008","unstructured":"Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB et al (2008) Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 93(11):4245\u20134253","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1445_CR18","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1210\/js.2017-00328","volume":"1","author":"RP Millar","year":"2017","unstructured":"Millar RP, Sonigo C, Anderson RA, George J, Maione L, Brailly-Tabard S et al (2017) Hypothalamic-pituitary-ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women with Chronic Amenorrhea. J Endocr Soc 1(11):1362\u20131371","journal-title":"J Endocr Soc"},{"key":"1445_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-030-11836-5_11","volume-title":"Prolactin disorders: from Basic Science to Clinical Management","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Prolactinomas in men. In: Tritos NA, Klibanski A (eds) Prolactin disorders: from Basic Science to Clinical Management. Springer International Publishing, Cham, pp 189\u2013204"},{"issue":"2","key":"1445_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12020-018-1765-3","volume":"63","author":"MC Burlacu","year":"2019","unstructured":"Burlacu MC, Maiter D, Duprez T, Delgrange E (2019) T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63(2):323\u2013331","journal-title":"Endocrine"},{"issue":"6","key":"1445_CR21","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/cen.12768","volume":"83","author":"LA Cooper","year":"2015","unstructured":"Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM (2015) The association of obesity with sex hormone-binding globulin is stronger than the association with ageing\u2013implications for the interpretation of total testosterone measurements. Clin Endocrinol (Oxf) 83(6):828\u2013833","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1445_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1373\/clinchem.2018.289355","volume":"65","author":"A Singh","year":"2019","unstructured":"Singh A, Dobs AS (2019) Is it Time to test the Effect of Weight loss on Testosterone? Clin Chem 65(1):48\u201350","journal-title":"Clin Chem"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01445-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01445-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01445-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:56:13Z","timestamp":1730868973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01445-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01445-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"6 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Saint Luc University Hospital (IRB reference 2022\/13JUL\/280) approved this study and patient\u2019s informed consent was waived due to the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}